Handgrip Strength
Conditions
Brief summary
The efficacy of B-hydroxy-β-methybutyrate in sarcopenia
Interventions
DIETARY_SUPPLEMENTHMB
EEN+HMB
Sponsors
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with active Crohn's disease (CD) who visited the Sixth Affiliated Hospital of Sun Yat-sen University between July 2023 and December 2024; 2. Aged 18-50 years; 3. Complicated with sarcopenia; 4. Willing and able to tolerate oral exclusive enteral nutrition (EEN) therapy; 5. Signed informed consent and able to comply with the study procedures; 6. Colonic or ileocolonic type CD (SES-CD ≥6; if only terminal ileum is involved, SES-CD ≥4).
Exclusion criteria
1. Short bowel syndrome; 2. High-output jejunal fistula; 3. Severe stress or shock status; 4. Complete mechanical intestinal obstruction, acute gastrointestinal bleeding, or severe intra-abdominal infection; 5. Severe hepatic, renal, or cardiac diseases, or malignant tumors; 6. History of allergy or contraindication to Ensure or HMB; 7. Persistent severe vomiting or intractable diarrhea; 8. Congenital disorders of sugar or amino acid metabolism; 9. Underwent CD-related intestinal surgery or received biologic therapy within the past month, or received immunosuppressive/antibiotic therapy related to CD within 2 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| muscle strength improvement | Week 4; Week 8 | Grip strength was measured using an electronic dynamometer. Participants sat in an armchair with the upper arm in the adducted neutral position, the elbow flexed at 90°, and the forearm and wrist relaxed naturally. The test hand held the dynamometer and was instructed to squeeze with maximal force smoothly until reaching the peak value, without any twisting or jerking movements of the forearm or hand. After completing the measurement, the other hand was tested using the same method. Each trial was performed three times per hand with a one-minute interval between trials. The maximum value among the six trials was recorded as the final result. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of muscle mass | Week 4; Week 8 | Appendicular skeletal muscle mass (ASM) was assessed in this study using a body composition analyzer. ASM was defined as the sum of muscle mass in the arms and legs. During the measurement, patients were required to fast, empty their bowels and bladder, wear light clothing, and undergo the test before exercise, bathing, or showering. Female patients were instructed to avoid measurements during menstruation. |
| Clinical response | Week 4; Week 8 | A decrease in the Crohn's Disease Activity Index (CDAI) by ≥70 points or a CDAI \<150. |
| Clinical remission | Week 4; Week 8 | CDAI \<150. |
| Mucosal healing | Week 4; Week 8 | No visible ulcers on endoscopy. |
| Clinical relapse | Week 4; Week 8 | CDAI ≥250 at any visit, or CDAI between 150-250 at two consecutive visits one week apart, with an increase of at least 70 points, accompanied by either CRP \>5 mg/L or fecal calprotectin \>250 μg/g. |
Countries
China
Outcome results
None listed